@article{MTMT:1369693,
	title = {Comparison of photon with electron boost in treatment of early stage breast cancer},
	url = {https://m2.mtmt.hu/api/publication/1369693},
	author = {Kovács, Árpád and Hadjiev, Janaki and Lakosi, Ferenc and Glavák, Csaba and Antal, Gergely and Bogner, Péter and Horváth, Ákos and Repa, Imre},
	doi = {10.1007/s12253-008-9015-2},
	journal-iso = {PATHOL ONCOL RES},
	journal = {PATHOLOGY AND ONCOLOGY RESEARCH},
	volume = {14},
	unique-id = {1369693},
	issn = {1219-4956},
	abstract = {In the treatment of early stage breast cancer breast conserving surgery (BCS) followed by whole breast irradiation (WBI) is a standard method. The impact of the tumor bed boost following WBI is well-defined, but there are various delivery methods. In this study the electron and the photon boost techniques were compared. For 78 early stage breast cancer patients both CT based 3D conformal photon boost and electron boost plans were created. For dosimetric comparison coverage index (CI), external volume index (EI) and conformality index (COIN) were studied. Lung volume receiving a dose of 2 Gy was also reviewed. Seventy-eight patients with 156 plans were compared. The mean tumor bed volume was measured as 61.39 cm3 the mean tumor bed-skin distance was 3.13 cm. In the case of CI and COIN significant differences were found in favor of the photon boost. In the comparison of EI no significant difference was detected between the two techniques. The mean lung volume receiving 2 Gy were 42.3 and 168.35 cm3, for photons and electrons respectively. In the adjuvant treatment of early stage breast cancer WBI followed by conformal photon boost showed to be superior to electron boost in focus of the COIN and CI.},
	year = {2008},
	eissn = {1532-2807},
	pages = {193-197},
	orcid-numbers = {Kovács, Árpád/0000-0002-8469-5764; Hadjiev, Janaki/0000-0003-4419-353X; Glavák, Csaba/0000-0003-1448-810X; Antal, Gergely/0000-0002-9259-6643}
}

@article{MTMT:1118079,
	title = {Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy--4-year results of a randomized trial.},
	url = {https://m2.mtmt.hu/api/publication/1118079},
	author = {Lovey, K and Fodor, János and Major, Tibor and Szabo, E and Orosz, Zsolt and Sulyok, Z and Jánváry, Zsolt Levente and Fröhlich, Georgina and Kásler, Miklós and Polgár, Csaba},
	doi = {10.1016/j.ijrobp.2007.03.055},
	journal-iso = {INT J RADIAT ONCOL},
	journal = {INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS},
	volume = {69},
	unique-id = {1118079},
	issn = {0360-3016},
	abstract = {PURPOSE: To examine the incidence and clinical relevance of fat necrosis after
		accelerated partial-breast irradiation (PBI) using interstitial high-dose-rate
		brachytherapy (HDR-BT) in comparison with partial-breast electron irradiation
		(ELE) and whole-breast irradiation (WBI). METHODS AND MATERIALS: Between 1998 and
		2004, 258 early-stage breast cancer patients were randomized to receive 50 Gy WBI
		(n = 130) or PBI (n = 128). The latter consisted of either 7 x 5.2 Gy HDR-BT (n =
		88) or 50 Gy ELE (n = 40). The incidence of fat necrosis, its impact on cosmetic 
		outcome, accompanying radiologic features, and clinical symptoms were evaluated. 
		RESULTS: The 4-year actuarial rate of fat necrosis was 31.1% for all patients,
		and 31.9%, 36.5%, and 17.7% after WBI, HDR-BT and ELE, respectively
		(p(WBI/HDR-BT) = 0.26; p(WBI/ELE) = 0.11; p(ELE/HDR-BT) = 0.025). The respective 
		rate of asymptomatic fat necrosis was 20.2%, 25.3%, and 10% of patients. The
		incidence of symptomatic fat necrosis was not significantly different after WBI
		(8.5%), HDR-BT (11.4%), and ELE (7.5%). Symptomatic fat necrosis was
		significantly associated with a worse cosmetic outcome, whereas asymptomatic fat 
		necrosis was not. Fat necrosis was detectable with mammography and/or ultrasound 
		in each case. Additional imaging examinations were required in 21% of cases and
		aspiration cytology in 42%. CONCLUSIONS: Asymptomatic fat necrosis is a common
		adverse event of breast-conserving therapy, having no significant clinical
		relevance in the majority of the cases. The incidence of both symptomatic and
		asymptomatic fat necrosis is similar after conventional WBI and accelerated
		partial-breast HDR-BT.},
	keywords = {Follow-Up Studies; Aged; Adult; Female; Middle Aged; Humans; Aged, 80 and over; Incidence; Radiotherapy Dosage; Breast Neoplasms/*radiotherapy; Fat Necrosis/*epidemiology/etiology/radiography; Electrons/adverse effects/therapeutic use; Breast/*pathology/radiation effects; Brachytherapy/adverse effects/methods},
	year = {2007},
	eissn = {1879-355X},
	pages = {724-731},
	orcid-numbers = {Major, Tibor/0000-0002-4672-6910; Jánváry, Zsolt Levente/0000-0002-4583-4901; Fröhlich, Georgina/0000-0001-6428-6536; Kásler, Miklós/0000-0002-7235-8787; Polgár, Csaba/0000-0001-7245-0762}
}

@article{MTMT:1118041,
	title = {The role of boost irradiation in the conservative treatment of stage I-II breast cancer.},
	url = {https://m2.mtmt.hu/api/publication/1118041},
	author = {Polgár, Csaba and Fodor, János and Major, Tibor and Orosz, Zsolt and Németh, György},
	doi = {10.1007/BF03032380},
	journal-iso = {PATHOL ONCOL RES},
	journal = {PATHOLOGY AND ONCOLOGY RESEARCH},
	volume = {7},
	unique-id = {1118041},
	issn = {1219-4956},
	abstract = {In this article, we review the current status, indication, technical aspects,
		controversies, and future prospects of boost irradiation after breast conserving 
		surgery (BCS). BCS and radiotherapy (RT) of the conserved breast became widely
		accepted in the last decades for the treatment of early invasive breast cancer.
		The standard technique of RT after breast conservation is to treat the whole
		breast up to a total dose of 45 to 50 Gy. However, there is no consensus among
		radiation oncologists about the necessity of boost dose to the tumor bed.
		Generally accepted criteria for identification of high risk subgroups, in which
		boost is recommended, have not been established yet. Further controversy exists
		regarding the optimal boost technique (electron vs. brachytherapy), and their
		impact on local tumor control and cosmesis. Based on the results of numerous
		retrospective and recently published prospective trials, the European
		brachytherapy society (GEC-ESTRO), as well as the American Brachytherapy Society 
		has issued their guidelines in these topics. These guidelines will help
		clinicians in their medical decisions. Some aspects of boost irradiation still
		remain somewhat controversial. The final results of prospective boost trials with
		longer follow-up, involving analyses based on pathologically defined subgroups,
		will clarify these controversies. Preliminary results with recently developed
		boost techniques (intraoperative RT, CT-image based 3D conformal brachytherapy,
		and 3D virtual brachytherapy) are promising. However, more experience and longer 
		follow-up are required to define whether these methods might improve local tumor 
		control for breast cancer patients treated with conservative surgery and RT.},
	keywords = {Adult; Female; Middle Aged; Humans; Neoplasm Staging; Treatment Outcome; Clinical Trials as Topic; Radiation Dosage; Brachytherapy; Mastectomy, Segmental; Breast Neoplasms/*pathology/*radiotherapy/surgery},
	year = {2001},
	eissn = {1532-2807},
	pages = {241-250},
	orcid-numbers = {Polgár, Csaba/0000-0001-7245-0762; Major, Tibor/0000-0002-4672-6910}
}